Salud financiera de hoja de balance de enVVeno Medical

Salud financiera controles de criterios 6/6

enVVeno Medical tiene un patrimonio de los accionistas total de $46.2M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $48.6M y $2.4M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$42.94m
Patrimonio	US$42.37m
Total pasivo	US$2.46m
Activos totales	US$44.83m

Actualizaciones recientes sobre salud financiera

Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth

Mar 07

Recent updates

Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth

Mar 07

Will enVVeno Medical (NASDAQ:NVNO) Spend Its Cash Wisely?

Aug 14

Is enVVeno Medical (NASDAQ:NVNO) In A Good Position To Deliver On Growth Plans?

Apr 22

We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

Dec 21

enVVeno Medical: Unique Exposure To Venous Treatment Domain

Sep 23

We're Hopeful That enVVeno Medical (NASDAQ:NVNO) Will Use Its Cash Wisely

Aug 23

enVVeno Medical reports Q2 results

Aug 03

We Think enVVeno Medical (NASDAQ:NVNO) Can Afford To Drive Business Growth

May 10

We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

Jan 25

Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics

Sep 08

Hancock Jaffe Laboratories finance chief sheds interim tag

Dec 31

Hancock Jaffe approves 1:25 reverse stock split

Nov 27

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($46.9M) de NVNO superan a sus pasivos a corto plazo ($1.4M).

Pasivo a largo plazo: Los activos a corto plazo de NVNO ($46.9M) superan a sus pasivos a largo plazo ($1.1M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: NVNO está libre de deudas.

Reducción de la deuda: NVNO no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: NVNO tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: NVNO dispone de suficiente cash runway para 2.1 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 24.4% cada año.

Salud financiera de hoja de balance de enVVeno Medical

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth

Will enVVeno Medical (NASDAQ:NVNO) Spend Its Cash Wisely?

Is enVVeno Medical (NASDAQ:NVNO) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

We're Hopeful That enVVeno Medical (NASDAQ:NVNO) Will Use Its Cash Wisely

We Think enVVeno Medical (NASDAQ:NVNO) Can Afford To Drive Business Growth

Recent updates

enVVeno Medical Corporation Announces Additional Topline Efficacy Data from the VenoValve U.S. Pivotal Trial to Be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024

enVVeno Medical Corporation Appoints Andrew Cormack as Its Chief Commercial Officer

Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth

enVVeno Medical Corporation Announces the Presentation of Positive Topline Efficacy Data Showing Significant Clinical Improvement from the Savve U.S. Pivotal Trial for the Venovalve

New minor risk - Share price stability

Forecast to breakeven in 2026

enVVeno Medical Corporation Presents Positive Preliminary Device Related Material Adverse Event Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium

enVVeno Medical Corporation, Annual General Meeting, Dec 05, 2023

New minor risk - Shareholder dilution

Price target decreased by 15% to US$20.40

enVVeno Medical Corporation Achieves Full Enrollment for VenoValve U.S. Pivotal Trial

Will enVVeno Medical (NASDAQ:NVNO) Spend Its Cash Wisely?

New major risk - Share price stability

Envveno Medical Corporation Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study

New minor risk - Share price stability

Is enVVeno Medical (NASDAQ:NVNO) In A Good Position To Deliver On Growth Plans?

Envveno Medical Promotes Hamed Alavi to Senior Vice President and Chief Technology Officer

We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

Envveno Medical Corporation Presents Positive Long-Term, Three-Year Observational Data from A Cohort of Patients That Participated in the Previously Concluded Venovalve First-In-Human Clinical Tria

Insufficient new directors

enVVeno Medical Successfully Passes Preliminary FDA Safety Review for the VenoValve U.S. Pivotal Study

enVVeno Medical Corporation, Annual General Meeting, Nov 30, 2022

Insufficient new directors

Insufficient new directors

enVVeno Medical: Unique Exposure To Venous Treatment Domain

We're Hopeful That enVVeno Medical (NASDAQ:NVNO) Will Use Its Cash Wisely

enVVeno Medical reports Q2 results

We Think enVVeno Medical (NASDAQ:NVNO) Can Afford To Drive Business Growth

Price target decreased to US$24.00

No longer forecast to breakeven

We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

Hancock Jaffe Laboratories, Inc Begins Enrollment for the U.S. Pivotal Trial for the Venovalve, Potential Treatment for Deep Venous Chronic Venous Insufficiency

Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics

Price target decreased to US$26.00

Forecast to breakeven in 2024

New 90-day low: US$7.37

Price target lowered to US$28.00

Hancock Jaffe Laboratories, Inc. has completed a Composite Units Offering in the amount of $35.999992 million.

Hancock Jaffe Laboratories, Inc. Appoints Craig Glynn Chief Financial Officer

Hancock Jaffe Laboratories finance chief sheds interim tag

Hancock Jaffe Receives Formal Notification from the Nasdaq Hearings Panel

Hancock Jaffe approves 1:25 reverse stock split

Hancock Jaffe Laboratories, Inc. announced delayed 10-Q filing

Hancock Jaffe Laboratories, Inc., Annual General Meeting, Dec 17, 2020

Hancock Jaffe Laboratories, Inc. (NasdaqCM:HJLI) entered into non-binding letter of intent to acquire Catheter Precision, Inc.

New 90-day high - US$0.56

New 90-day low - US$0.31

Hancock Jaffe Regains Compliance with Nasdaq Stockholder's Equity Rule

New 90-day low - US$0.31

Hancock Jaffe Laboratories, Inc. announced that it has received $1.556 million in funding

Hancock Jaffe Laboratories, Inc. has completed a Composite Units Offering in the amount of $4 million.

Hancock Jaffe Laboratories, Inc. announced that it expects to receive $1.556 million in funding

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera